Mantle Cell Lymphoma - 35 Studies Found
Active, not recruiting |
: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2011-03-24 :
|
Completed |
: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2007-12-19 : Drug: modified Hyper-CVAD rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorub |
Completed |
: Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2007-12-19 :
|
Active, not recruiting |
: Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) : Mantle Cell Lymphoma : 2011-08-16 :
|
Terminated |
: A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2009-02-12 : Drug: P276-00 P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 m |
Recruiting |
: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2016-07-19 : Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim |
Active, not recruiting |
: Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2012-06-26 : Drug: Rituximab, Bendamustine, Cytarabine. 6 cycles of 28 days with Rituximab, Bendamustine and Cytarabi |
Completed |
: Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) : MANTLE CELL LYMPHOMA : 2008-11-05 : Drug: Lenalidomide and Dexametasone Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral ad |
Terminated |
: Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma : Mantle Cell Lymphoma : 2009-02-18 : Drug: ZARNESTRA (Tipifarnib) |
Completed |
: Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years : Mantle Cell Lymphoma : 2006-01-31 :
|